Moxilubant
Based on 1 publication(s) in Google Scholar
Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease.
For research use only. We do not sell to patients.
- Purity: 99.83%
- CAS No.: 146978-48-5
- Formula: C26H37N3O4
- Molecular Weight:455.59
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Orally Active Compound Library
HY-L061
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Moxilubant
MoreAll Leukotriene Receptor Isoforms
More
Biological Activity
Moxilubant (oral administration; single dose) dose-dependently inhibits LTB4-induced neutropenia in rats, with ED50 values ranging from 2 mg/kg to 11 mg/kg within 1 to 18 hours post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/CBYJ mice treated Arachidonic acid[1]
-
Dosage:0.1 mg/kg; 1.0 mg/kg; 3.0 mg/kg; 10.0 mg/kg
-
Administration:p.o.; single dose
-
Result:Caused a 19% reduction in edema and a 4% change in MPO activity at 0.1 mg/kg (1.5 hours post-dose).
Caused a 41% reduction in edema and a 39% reduction in MPO activity at 1.0 mg/kg (1.5 hours post-dose).
Caused a 65% reduction in edema and a 76% reduction in MPO activity at 3.0 mg/kg (1.5 hours post-dose).
Reached an ED50 of 1.4 mg/kg for edema inhibition and 1.2 mg/kg for MPO activity inhibition (1.5 hours post-dose).
Caused a 24% reduction in edema and a 3% increase in MPO activity at 1.0 mg/kg (18 hours post-dose).
Caused a 47% reduction in edema and a 25% reduction in MPO activity at 3.0 mg/kg (18 hours post-dose).
Caused a 55% reduction in edema and a 58% reduction in MPO activity at 10.0 mg/kg (18 hours post-dose).
Reached an ED50 of 5.7 mg/kg for edema inhibition and 7.7 mg/kg for MPO activity inhibition (18 hours post-dose).
Chemical Information
-
CAS No. 146978-48-5
-
Appearance Solid
-
Molecular Weight 455.59
-
Formula C26H37N3O4
-
Color White to off-white
-
SMILES
CC(C)N(C(C)C)C(C1=CC(OC)=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)=O
-
Synonyms
CGS 25019C free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Med Chem
Discovery of Chromone Derivatives as Selective BLT1 Inhibitors for Alleviating Acute Lung Injury and Sepsis. [Abstract]2026 Feb 26;69(4):4361-4390. PMID: 41696851
Solvent & Solubility
DMSO : 62.5 mg/mL (137.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Raychaudhuri A, et al. Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res. 1995 Aug;44 Suppl 2:S141-2. [Content Brief]
[2]. Bhatt L, et al. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017;33:65-73. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1950 mL | 10.9748 mL | 21.9496 mL | 54.8739 mL |
| 5 mM | 0.4390 mL | 2.1950 mL | 4.3899 mL | 10.9748 mL | |
| 10 mM | 0.2195 mL | 1.0975 mL | 2.1950 mL | 5.4874 mL | |
| 15 mM | 0.1463 mL | 0.7317 mL | 1.4633 mL | 3.6583 mL | |
| 20 mM | 0.1097 mL | 0.5487 mL | 1.0975 mL | 2.7437 mL | |
| 25 mM | 0.0878 mL | 0.4390 mL | 0.8780 mL | 2.1950 mL | |
| 30 mM | 0.0732 mL | 0.3658 mL | 0.7317 mL | 1.8291 mL | |
| 40 mM | 0.0549 mL | 0.2744 mL | 0.5487 mL | 1.3718 mL | |
| 50 mM | 0.0439 mL | 0.2195 mL | 0.4390 mL | 1.0975 mL | |
| 60 mM | 0.0366 mL | 0.1829 mL | 0.3658 mL | 0.9146 mL | |
| 80 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.6859 mL | |
| 100 mM | 0.0219 mL | 0.1097 mL | 0.2195 mL | 0.5487 mL |
Moxilubant Related Classifications
HY-106929 Related Classifications
Powered by Bioz